Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

World’s most populous country gains access to Medtronic’s newest TAVR valve
Medtronic developed the self-expanding Evolut FX+ TAVR system with improved coronary access in mind. The FDA-approved device has now officially launched in India.
New registry helps hospitals expand outpatient services for heart patients
The initiation of the ACC Ambulatory Surgical Center Registry comes at a time when hospitals are expanding their structural heart programs. The registry is providing valuable details about which patients should stay at the hospital and which can be treated in an outpatient setting.
TAVR still a safe option for patients with nickel allergies
More research is still needed, as this study only included data from a small number of patients, but TAVR was not linked to any severe adverse events or allergic reactions.
Why patient selection is so important when performing M-TEER
As mitral transcatheter edge-to-edge repair continues to gain momentum in the United States, a new study of CMS data examines what happens to patient outcomes when the procedure fails.
Advances in electrosurgical techniques have helped thousands of transcatheter valve patients
Toby Rogers, MD, associate professor of medicine at Georgetown University and an interventional cardiologist at MedStar, explains how electrosurgical procedures for transcaval access have helped large numbers of patients receive transcatheter heart valves who otherwise would have been disqualified due to anatomical issues.

heart data research doctor cardiologist AI

TAVR patients with moderate or greater TR may face increased risks

When TAVR patients present with moderate or greater tricuspid regurgitation, it could impact the care team's treatment strategy of choice.

SS Innovations International SSi Mantra 3 robotic surgery system

Robotic heart surgery represents a key step forward for SS Innovations

The company's SSi Mantra 3 robotic surgery system has already gained regulatory approvals in several countries. FDA approval is anticipated by late 2025 or early 2026.

Statue of Liberty New York City healthcare

Late-breaking clinical trials announced for New York Valves 2025

The three-day event is now in its second year. Each day will feature late-breaking clinical trials focused on a different heart valve.

Next-day discharge after TAVR is still safe when alternative access is required

Even TAVR patients not treated using transfemoral access can typically go home the very next day.

Q&A: Cardiologist and EARLY TAVR co-author questions study’s execution

The EARLY TAVR clinical trial made a significant impact, paving the way for the FDA to approve multiple transcatheter heart valves for the treatment of asymptomatic patients. However, one cardiologist who participated in the trial has some serious concerns with how its findings were presented to the public.

cardiologists heart doctors heart research heart data

Balloon-expandable, self-expanding TAVR valves associated with comparable long-term outcomes

Patients treated with the Sapien 3 platform from Edwards Lifesciences and the Evolut platform from Medtronic were linked to more similarities than differences after six years. This was a single-center study, researchers noted, but it does provide an in-depth look at the safety and effectiveness of TAVR.

‘A compelling alternative’: Polymer heart valve receives first commercial approval of its kind

A new surgical mitral valve from Foldax will now be commercially available in India. The valve is built using LifePolymer, a proprietary material that does not include animal tissue.

A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]

TAVR specialists come together to explore new data, patient selection and much more

Care teams have a lot to consider when choosing the right treatment for patients with severe aortic stenosis. Two cardiologists and a veteran cardiothoracic surgeon are taking part in a new webinar focused on that very topic.

Structural Heart Disease

World’s most populous country gains access to Medtronic’s newest TAVR valve

New registry helps hospitals expand outpatient services for heart patients

TAVR still a safe option for patients with nickel allergies

Why patient selection is so important when performing M-TEER

Advances in electrosurgical techniques have helped thousands of transcatheter valve patients